Full-Time

Associate Scientific Director – Project Lead

Synthetic Molecule DS

Updated on 9/3/2026

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$154.4k - $242.6k/yr

+ Short-term incentives + Long-term incentives + 401(k) match

Cambridge, MA, USA

Hybrid

Hybrid work in Cambridge, Massachusetts is required.

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
LLM
GMP
Risk Management

Get referred to Takeda

See people who can refer or advise you

Requirements
  • A bachelor's degree and 15 or more years of relevant industry experience, or a master's degree and 13 or more years of relevant industry experience, or a PhD and 7 or more years of relevant industry experience.
  • Demonstrated experience in synthetic small-molecule drug-substance process development.
  • Demonstrated experience supporting late-stage, cross-functional development teams in a leadership capacity with full accountability for synthetic-molecule chemistry and/or engineering deliverables, such as Chemistry Lead, Engineering Lead, or Drug Substance Lead.
  • Experience managing work executed by internal development teams, including defining and prioritizing work packages, translating overall program objectives into clear deliverables, driving accountability through matrix leadership, and leading issue resolution to ensure high-quality execution.
  • Experience managing work executed by external partners such as contract development and manufacturing organizations, including partner selection and qualification, governance and oversight, technology-transfer support, work-package execution, issue resolution and escalation, and vendor-performance management.
  • Working knowledge of current Good Manufacturing Practices applicable to synthetic-molecule drug-substance manufacturing.
  • Proven ability to work effectively in a multidisciplinary, matrixed team environment.
  • Structured analytical and problem-solving capability to troubleshoot complex technical and program issues, determine root cause, and drive risk-based resolution across stakeholders.
  • Proven ability to lead through matrix influence on global, cross-functional teams and build alignment across technical, quality, operations, and governance stakeholders without formal authority.
  • Strong verbal and written communication skills, including clear documentation of issues, decisions, risks, and mitigation plans, and technical writing skills to support internal technical documents and Chemistry, Manufacturing, and Controls content.
  • Fluency in English, written and spoken, sufficient to perform the essential functions of the role in a global business environment.
  • Strong working knowledge of synthetic small-molecule drug-substance process development and late-stage manufacturing interfaces.
  • Working knowledge of process characterization and process validation principles, including phase-appropriate deliverables, validation-readiness expectations, and execution planning.
  • Demonstrated ability to apply Quality by Design principles across drug-substance and process-validation deliverables, including practical risk assessment, control-strategy concepts, and knowledge-management discipline.
  • Risk and issue management capability, including proactively identifying and communicating risk posture, developing mitigation plans with owners and timelines, driving follow-through, and escalating with options and recommendations.
  • Governance and decision-framing skills to prepare governance-ready narratives and materials and frame trade-offs and recommendations for timely leadership decisions.
  • Quality mindset and Good Manufacturing Practice documentation discipline, with working knowledge of applicable standard operating procedures and operating-model requirements and a focus on inspection readiness.
  • Digital fluency and responsible use of approved generative artificial intelligence tools to improve cross-functional execution, transparency, and decision readiness, with human review, traceability, and protection of confidential information.
  • Facilitation, coordination, and project-management discipline, including planning, tracking, dependency management, and action and decision documentation across multiple workstreams.
  • External-partner governance capability, including collaboration with contract development and manufacturing organizations and vendors, technical communication, issue escalation, and vendor-performance management.
  • Strong organization and prioritization skills to balance timelines, scope, and resource constraints while maintaining disciplined fiscal stewardship.
  • Capability-building and continuous-improvement mindset, including mentoring and coaching junior Drug Substance Leadership and Process Validation Leadership professionals, participating in Community of Practice activities, and contributing to standards, templates, and job aids.
Responsibilities
  • Provide cross-functional Drug Substance Leadership for late-stage synthetic-molecule programs, ensuring phase-appropriate drug-substance strategy and consistent, high-quality execution aligned to global standards and the Synthetic Molecule Process Development drug-substance operating model.
  • Provide Process Validation Leadership beginning at Process Characterization Assessment, driving validation strategy, readiness, and execution through late-stage deliverables in alignment with governance, quality, and inspection-readiness expectations.
  • Integrate program resources, including budget, timelines, priorities, and broader program context, to prioritize, allocate, and sequence Synthetic Molecule Process Development drug-substance working-team activities in a phase-appropriate, risk-aligned manner; frame trade-offs and ensure disciplined fiscal stewardship.
  • Ensure application of Quality by Design principles across drug-substance and process-validation deliverables, including criticality assessment, control-strategy concepts, risk assessments, and knowledge management.
  • Own the program-level drug-substance and process-validation risk posture by identifying, documenting, and communicating risks and issues; developing mitigation plans with owners and timelines; driving follow-through; and escalating options and recommendations to stakeholders and leadership.
  • Develop organizational capability through mentoring and coaching junior Drug Substance Leadership and Process Validation Leadership professionals, including onboarding, peer review of key deliverables, and sharing best practices.
  • Lead or contribute to cross-functional initiatives that improve the synthetic-molecule drug-substance operating model and ways of working, including standard operating procedures, job aids, templates, and leadership playbooks.
  • Support due diligence and late-stage pipeline assessments by leading or partnering on technical evaluations, drug-substance and process-validation risk-posture assessments, and integration recommendations.
  • Represent Takeda in cross-industry consortia and external forums, contributing subject-matter-expert perspective, sharing best practices, and translating external insights into internal standards and improvements for drug-substance and process-validation strategy, governance, and ways of working.
Desired Qualifications
  • Demonstrated experience in pivotal process design, criticality assessment, and establishment of process design space and control strategy.
  • Experience partnering with manufacturing organizations to plan and execute manufacturing campaigns in compliance with current Good Manufacturing Practices, with leadership of late-stage process performance qualification and validation readiness activities preferred.
  • Experience contributing to Chemistry, Manufacturing, and Controls regulatory submissions or supporting responses to Health Authority questions, with late-stage filing experience preferred.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 FDA approval of MIMRYLO opened a new U.S. polycythemia vera franchise.
  • ORZEYFUL won U.S., Japan, and China approvals in August 2026, accelerating commercialization.
  • Takeda maintained FY2026 guidance after Q1 2026, with 22.6% growth from new launches.

What critics are saying

  • The May 18, 2026 Amitiza verdict imposed $884.9 million damages, tripling on judgment.
  • Takeda's March 2026 restructuring cuts 4,500 jobs, signaling margin pressure and execution disruption.
  • If ORZEYFUL, MIMRYLO, and zasocitinib underperform, Takeda's mature-brands decline crushes growth.

What makes Takeda unique

  • Takeda’s 2026 launches target first-in-class mechanisms: MIMRYLO, ORZEYFUL, and zasocitinib.
  • Takeda built rare Japan-to-global R&D depth, with oveporexton approved in China, U.S., Japan.
  • Takeda paired discovery teams with Boltz in 2026, embedding AI across research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 31st, 2026
Takeda wins FDA approval for first-in-class blood cancer drug, triggering $275M payment to Protagonist

The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.

Associated Press
Aug 28th, 2026
US FDA approves Takeda's Mimrylo for polycythemia vera treatment

Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.

Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.

Yahoo Finance
Aug 5th, 2026
FDA approves Takeda's Orzeyful, first medicine to treat underlying cause of narcolepsy type 1

The US Food and Drug Administration has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first orexin receptor 2 agonist approved to address the underlying cause of the disease rather than individual symptoms. Narcolepsy type 1 is a chronic neurological disease affecting approximately 120,000 people in the US. It is driven by orexin deficiency and causes excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted sleep. Clinical trials showed adults taking ORZEYFUL experienced significant improvements across the full range of symptoms compared to placebo. Takeda is preparing for the US launch, which will proceed following completion of the Drug Enforcement Administration scheduling process. The company describes the approval as potentially redefining how narcolepsy type 1 is managed.

GeekWire
Jul 31st, 2026
AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

Seattle-based biotech startup Accipiter Biosciences has raised an additional $10.5 million, less than a year after emerging from stealth with $12.7 million. The funding, from existing investors including Flying Fish Partners and Takeda, will accelerate the company's drug development programmes. The startup uses AI tools developed at the University of Washington's Institute for Protein Design to engineer proteins that can bind multiple cellular targets simultaneously. The company has expanded to 22 employees, including researchers who worked under Nobel laureate David Baker. Accipiter Bio has partnerships with Pfizer and Gilead Sciences-owned Kite Pharma, with potential milestone payments exceeding $330 million. The additional funding will enable the company to advance three or four drug candidates into clinical trials, focusing on immunology and oncology.